Nanopharma Development LLC

Importer · Russia

Pharmaceutical R&D; production of nano based drug delivery systems for cancer, HIV, transplantation (oncology, immunosup

About Nanopharma Development LLC

Founded in 2013 as part of Russia’s Tatarstan nanotechnology cluster, Nanopharma Development LLC (owned by Izvarino Pharma and RUSNANO) operates a lab industrial complex at Technopolis “Himgrad” in Kazan. With over 559 million RUB investment, it specializes in nanoformulated generics—solid dosage delivery systems such as Imatinib, Tacrolimus, and Valganciclovir (Tsivalgan)—addressing cancer, transplant, and HIV therapies, supplying state listed essential medicines and aiming for a portfolio of 10 generics dnb.com+8tpidea.ru+8tpidea.ru+8. Founded in 2013 as part of Russia’s Tatarstan nanotechnology cluster, Nanopharma Development LLC (owned by Izvarino Pharma and RUSNANO) operates a lab industrial complex at Technopolis “Himgrad” in Kazan. With over 559 million RUB investment, it specializes in nanoformulated generics—solid dosage delivery systems such as Imatinib, Tacrolimus, and Valganciclovir (Tsivalgan)—addressing cancer, transplant, and HIV therapies, supplying state listed essential medicines and aiming for a portfolio of 10 generics dnb.com+8tpidea.ru+8tpidea.ru+8. Company LinkedIn URL: Not Available